Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $81
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) but lowers the price target from $83 to $81.

August 05, 2024 | 11:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Gena Wang maintains an Overweight rating on Ultragenyx Pharmaceutical but lowers the price target from $83 to $81.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100